Evidence for separation of HCV subtype 1a into two distinct clades

Summary.  The nucleotide sequence diversity present among hepatitis C virus (HCV) isolates allows rapid adjustment to exterior forces including host immunity and drug therapy. This viral response reflects a combination of a high rate of replication together with an error‐prone RNA‐dependent RNA polymerase, providing for the selection and proliferation of the viruses with the highest fitness. We examined HCV subtype 1a whole‐genome sequences to identify positions contributing to genotypic and phenotypic diversity. Phylogenetic tree reconstructions showed two distinct clades existing within the 1a subtype with each clade having a star‐like tree topology and lacking definite correlation between time or place of isolation and phylogeny. Identification of significant phylogenetically informative sites at the nucleotide level revealed positions not only contributing to clade differentiation, but which are located at or proximal to codons associated with resistance to protease inhibitors (NS3 Q41) or polymerase inhibitors (NS5B S368). Synonymous/nonsynonymous substitution mutation analyses revealed that the majority of nucleotide mutations yielded synonymous amino acids, indicating the presence of purifying selection pressure across the polyprotein with pockets of positive selection also being detected. Despite evidence for divergence at several loci, certain 1a characteristics were preserved including the length of the alternative reading frame/F protein (ARF/F) gene, and a subtype 1a‐specific phosphorylation site in NS5A (S349). Our analysis suggests that there may be strain‐specific differences in the development of antiviral resistance to viruses infecting patients who are dependent on the genetic variation separating these two clades.

[1]  F. Crick Codon--anticodon pairing: the wobble hypothesis. , 1966, Journal of molecular biology.

[2]  M. Nei,et al.  Simple methods for estimating the numbers of synonymous and nonsynonymous nucleotide substitutions. , 1986, Molecular biology and evolution.

[3]  Interaction of immune sera with synthetic peptides corresponding to the structural protein region of hepatitis C virus. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[4]  E. Holmes,et al.  Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. , 1993, The Journal of general virology.

[5]  R. Esteban,et al.  Epidemiology of hepatitis C virus infection. , 1993, Journal of hepatology.

[6]  M. Sakamoto,et al.  Characterization of the genomic sequence of type V (or 3a) hepatitis C virus isolates and PCR primers for specific detection. , 1993, The Journal of general virology.

[7]  J. Thompson,et al.  CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. , 1994, Nucleic acids research.

[8]  A. Prince,et al.  Characterization and mapping of a B-cell immunogenic domain in hepatitis C virus E2 glycoprotein using a yeast peptide library. , 1994, Virology.

[9]  N. Enomoto,et al.  Evolution and selection of hepatitis C virus variants in patients with chronic hepatitis C. , 1994, Virology.

[10]  R. Purcell,et al.  Genetic Heterogeneity of Hepatitis C Virus: Quasispecies and Genotypes , 1995, Seminars in liver disease.

[11]  D. Mindell,et al.  Positive selection and rates of evolution in immunodeficiency viruses from humans and chimpanzees. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[12]  N Enomoto,et al.  Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. , 1996, The New England journal of medicine.

[13]  M. Shapiro,et al.  Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[14]  R. Purcell,et al.  A hyperimmune serum against a synthetic peptide corresponding to the hypervariable region 1 of hepatitis C virus can prevent viral infection in cell cultures. , 1996, Virology.

[15]  B. Korber,et al.  Human immunodeficiency virus type 1 genetic evolution in children with different rates of development of disease , 1997, Journal of virology.

[16]  H. Thomas,et al.  Comparison of the rate of sequence variation in the hypervariable region of E2/NS1 region of hepatitis C virus in normal and hypogammaglobulinemic patients , 1998, Hepatology.

[17]  A. Kwong,et al.  Hepatitis C virus NS3/4A protease. , 1997, Antiviral research.

[18]  Z. Yang,et al.  Likelihood ratio tests for detecting positive selection and application to primate lysozyme evolution. , 1998, Molecular biology and evolution.

[19]  A. Zibert,et al.  Immunodominant B-cell domains of hepatitis C virus envelope proteins E1 and E2 identified during early and late time points of infection. , 1999, Journal of hepatology.

[20]  C. Rice,et al.  Identification of the Major Phosphorylation Site of the Hepatitis C Virus H Strain NS5A Protein as Serine 2321* , 1999, The Journal of Biological Chemistry.

[21]  A. Siddiqui,et al.  Human La antigen is required for the hepatitis C virus internal ribosome entry site-mediated translation. , 2000, The Journal of biological chemistry.

[22]  S. Zeuzem Hepatitis C virus: kinetics and quasispecies evolution during anti-viral therapy. , 2000, Forum.

[23]  H J Alter,et al.  The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. , 2000, Science.

[24]  Zhenming Xu,et al.  Synthesis of a novel hepatitis C virus protein by ribosomal frameshift , 2001, The EMBO journal.

[25]  D. Stump,et al.  Evidence for a new hepatitis C virus antigen encoded in an overlapping reading frame. , 2001, RNA.

[26]  Dieter Häussinger,et al.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. , 2002, The New England journal of medicine.

[27]  M. Unemo,et al.  Comparison of Serologic and Genetic porB-Based Typing of Neisseria gonorrhoeae: Consequences for Future Characterization , 2003, Journal of Clinical Microbiology.

[28]  P. Mavromara,et al.  Two Alternative Translation Mechanisms Are Responsible for the Expression of the HCV ARFP/F/Core+1 Coding Open Reading Frame* , 2003, Journal of Biological Chemistry.

[29]  P. Simmonds,et al.  Genetic diversity and evolution of hepatitis C virus--15 years on. , 2004, The Journal of general virology.

[30]  Edward C. Holmes,et al.  High-Resolution Phylogenetic Analysis of Hepatitis C Virus Adaptation and Its Relationship to Disease Progression , 2004, Journal of Virology.

[31]  Robert C. Edgar,et al.  MUSCLE: multiple sequence alignment with high accuracy and high throughput. , 2004, Nucleic acids research.

[32]  Todd M. Allen,et al.  Broad Repertoire of the CD4+ Th Cell Response in Spontaneously Controlled Hepatitis C Virus Infection Includes Dominant and Highly Promiscuous Epitopes1 , 2005, The Journal of Immunology.

[33]  S. Das,et al.  Human ribosomal protein L18a interacts with hepatitis C virus internal ribosome entry site , 2006, Archives of Virology.

[34]  C. Bréchot Hepatitis C virus , 1996, Digestive Diseases and Sciences.

[35]  Mark J. Schreiber,et al.  Establishment of a pipeline to analyse non-synonymous SNPs in Bos taurus , 2006, BMC Genomics.

[36]  T. Berg,et al.  Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. , 2006, Gastroenterology.

[37]  H. Conjeevaram,et al.  Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. , 2006, Gastroenterology.

[38]  R. Striker,et al.  Sensitivity of hepatitis C virus to cyclosporine A depends on nonstructural proteins NS5A and NS5B , 2007, Hepatology.

[39]  A. Kwong,et al.  Phenotypic and Structural Analyses of Hepatitis C Virus NS3 Protease Arg155 Variants , 2007, Journal of Biological Chemistry.

[40]  Todd M. Allen,et al.  Viral Sequence Evolution in Acute Hepatitis C Virus Infection , 2007, Journal of Virology.

[41]  Rick L. Stevens,et al.  National Institute of Allergy and Infectious Diseases Bioinformatics Resource Centers: New Assets for Pathogen Informatics , 2007, Infection and Immunity.

[42]  M. Nei,et al.  MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. , 2007, Molecular biology and evolution.

[43]  C. Rice,et al.  Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. , 2007, Gastroenterology.

[44]  Hengli Tang,et al.  Characterization of Hepatitis C Virus Subgenomic Replicon Resistance to Cyclosporine In Vitro , 2007, Journal of Virology.

[45]  Tara L. Kieffer,et al.  Telaprevir and pegylated interferon–alpha‐2a inhibit wild‐type and resistant genotype 1 hepatitis C virus replication in patients , 2007, Hepatology.

[46]  Milton W. Taylor,et al.  Pretreatment Sequence Diversity Differences in the Full-Length Hepatitis C Virus Open Reading Frame Correlate with Early Response to Therapy , 2007, Journal of Virology.

[47]  X. Tong,et al.  Analysis of HCV resistance mutations during combination therapy with protease inhibitor boceprevir and PEG-IFN alpha-2b using TaqMan mismatch amplification mutation assay. , 2008, Journal of virological methods.

[48]  A. Moya,et al.  Genetic variability in hepatitis C virus and its role in antiviral treatment response , 2007, Journal of viral hepatitis.

[49]  A. Moya,et al.  Hepatitis C virus and the controversial role of the interferon sensitivity determining region in the response to interferon treatment , 2008, Journal of medical virology.

[50]  R. Aurora,et al.  Hepatitis C Virus Diversity and Evolution in the Full Open-Reading Frame during Antiviral Therapy , 2008, PloS one.

[51]  A. Fomsgaard,et al.  The evolution of human influenza A viruses from 1999 to 2006: A complete genome study , 2008, Virology Journal.

[52]  B. McMahon,et al.  Hepatitis C virus envelope glycoprotein co-evolutionary dynamics during chronic hepatitis C. , 2008, Virology.

[53]  Todd M. Allen,et al.  Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment‐naïve patients , 2008, Hepatology.

[54]  O. Pybus,et al.  Evolution and dispersal of St. Louis encephalitis virus in the Americas. , 2009, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.